Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that:
ANXA3 can be detected in urine after standard digital rectal examination.
ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA
ANXA3 can help avoid unnecessary biopsies
ANXA3 can in the long run replace PSA as a marker
100 项与 ProteoSys AG 相关的临床结果
0 项与 ProteoSys AG 相关的专利（医药）
100 项与 ProteoSys AG 相关的药物交易
100 项与 ProteoSys AG 相关的转化医学
